R&D News | pharmaphorum

News

Sanofi builds case for Sarclisa, challenging J&J’s Darzalex

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma mark

News

Novavax gets $384m for clinical trial of COVID-19 vaccine

Global vaccine development organisation CEPI is to invest $384 million additional funding in a COVID-19 jab being developed by Novavax.

News

Genfit’s NASH hopes are dashed by phase 3 trial fail

Genfit has seen almost two-thirds of the value wiped off its shares after its much-anticipated pivotal trial of non-alcoholic steatohepatitis (NASH) drug elafibranor turned out

News

Doubts over US government plans for COVID-19 vaccine

There are doubts about the US government's plans to have 300 million COVID-19 vaccine doses ready by the end of the year, after the front-running candidate from Moderna advanced to mid-stag

News

Ferring’s gut microbiome drug clears phase 3 trial in C. dif...

Ferring Pharma has reported what it says is the first positive phase 3 trial of a microbiome therapy – based on healthy bacteria – showing it can reduce recurrences of a seriou

News

BerGenBio raises 45 million euros for COVID-19 drug developm...

Norway’s BerGenBio has raised 500 million Norwegian kroner – around $45.4 million euros – in an oversubscribed private placement to develop its pipeline that includes a potential COVID-19 t

Sanofi builds case for Sarclisa, challenging J&J’s Darzalex

Novavax gets $384m for clinical trial of COVID-19 vaccine

Genfit’s NASH hopes are dashed by phase 3 trial fail

Doubts over US government plans for COVID-19 vaccine

Ferring’s gut microbiome drug clears phase 3 trial in C. dif...

BerGenBio raises 45 million euros for COVID-19 drug developm...

Lilly inflates US facility investment spending by $4.5bn

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks